Andy Wolfe
andrewlwolfe.bsky.social
Andy Wolfe
@andrewlwolfe.bsky.social
Cancer researcher at Hunter College of the City University of New York & Weill Cornell Medicine. Views are my own.
Reposted by Andy Wolfe
Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer
www.jci.org
October 21, 2025 at 2:00 PM
Huge congrats to this year’s cohort of @damonrunyon SPARK postbacs -- especially @huntercollege alumni Subyeta Chowdhury and NY-RaMP alumni Imani Williams! damonrunyon.org/news/entries/8337/Damon%20Runyon%20announces%20newest%20class%20of%20SPARK%20Scholars
Damon Runyon announces newest class of SPARK Scholars
www.damonrunyon.org
October 23, 2025 at 2:24 AM
Reposted by Andy Wolfe
Damon Runyon mentor-mentee duo Piro Lito, MD, PhD, and Antonio Cuevas-Navarro, PhD, have developed a new approach to treating RAS-driven cancers, such as colorectal and pancreatic. Rather than inhibiting the cancerous protein, their drug restores its natural function. Read more:
New Discoveries and Honors in Cancer Research | Damon Runyon
www.damonrunyon.org
July 23, 2025 at 1:49 PM
Reposted by Andy Wolfe
Great stuff! Hunter College osteosarcoma researcher Shahana Mahajan has published a paper with new findings that have possible applications to many types of cancers. More: journals.plos.org/plosone/arti... #MihiCuraFuturi
Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity
KRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also...
journals.plos.org
October 14, 2025 at 8:22 PM
See How E.V. Road Trips Went From Impossible to Easy www.nytimes.com/interactive/...
See How E.V. Road Trips Went From Impossible to Easy (Gift Article)
There are a lot more fast chargers than there used to be. Look up what that could mean for a route near you.
www.nytimes.com
October 1, 2025 at 12:30 AM
Reposted by Andy Wolfe
Encouraging phase 1 results of an off-the-shelf, lymph node targeted #cancer vaccine targeting common #KRAS mutations (G12D, G12R) in pancreatic and colorectal cancer from Elicio $ELTX, @mskcancercenter.bsky.social, @mdanderson.bsky.social‪‬, UCLA & clinical collabs

www.nature.com/articles/s41...
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine
In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal ...
www.nature.com
August 14, 2025 at 3:17 PM
Reposted by Andy Wolfe
Congratulations to our @obenaufa.bsky.social on receiving the highly prestigious Dr. Josef Steiner Cancer Research Award 2025! 🎉

Read more in this interview with Anna: www.imp.ac.at/news/article...
September 12, 2025 at 4:01 PM
I am thrilled that our findings about using the Ras inhibitor daraxonrasib against osteosarcoma were just published in PLOS ONE! Many congrats to my co-authors Okkeun Jung, Angelene Soto, and Shahana Mahajan. dx.plos.org/10.1371/jour...
August 12, 2025 at 2:58 AM
Reposted by Andy Wolfe
The federal government’s demand of $1 billion from @UCLA would devastate the nation’s best public university, cut off life-saving care, halt tech and economic growth and reduce educational access.

Stand with UC to protect our vital mission: www.universityofcalifornia.edu/get-involved...
Stand Up for UC
www.universityofcalifornia.edu
August 8, 2025 at 11:02 PM
Exciting work!
July 25, 2025 at 2:36 PM
Reposted by Andy Wolfe
@cuny.edu Research in Focus looks at the work of Hunter College’s Climatologist and Professor of Geography and Environmental Science, William Solecki, who shows how we can design our public spaces to mitigate global warming. Read about it here: www.cuny.edu/news/resilie...
25 Colleges. One University.
www.cuny.edu
July 7, 2025 at 3:36 PM
Reposted by Andy Wolfe
Congratulations and bon voyage to Hunter College alumni Sajida Ahmed, Alison Juray, Andrew Loka, and Alp Doymaz, who will be traveling all over the world during the 2025 - 2026 academic year through the Fulbright Program! #HunterPride hunter.cuny.edu/news/four-fr...
June 24, 2025 at 4:19 PM
Reposted by Andy Wolfe
Excited to share our recent work published in PNAS last week uncovering the molecular mechanisms of PARP inhibitor resistance in BRCA2-deficient metastatic castration-resistant prostate cancer (mCRPC). Check out our manuscript!
June 12, 2025 at 2:51 AM
Our amazing lab team, Spring 2025! A huge congratulations to the lab members about to earn their undergraduate degree, finish their postbaccalaureate program, begin graduate school, and begin medical school.
May 29, 2025 at 8:16 PM
Huge congratulations to Dr. Melinda Diver and her lab on the publication of this outstanding new study, "Transport and InsP8 gating mechanisms of the human inorganic phosphate exporter XPR1" in the journal Nature Communications today!
www.nature.com/articles/s41...
March 20, 2025 at 9:10 PM
I am thrilled that our review about the RNA-binding protein IMP2 was published today! Congratulations to my co-authors Jessica Das, Ottavia Busia-Bourdain, and Khizr Khan.
doi.org/10.3390/ijms...
March 7, 2025 at 8:28 PM
Reposted by Andy Wolfe
A long-awaited nonopioid pain drug has won approval from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain.
Nonopioid drug for acute pain wins FDA approval
Ongoing trials will reveal whether suzetrigine is also effective against chronic pain
scim.ag
January 31, 2025 at 6:21 PM
Reposted by Andy Wolfe
Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients. Learn more in a new Clinical Implications of Basic Research article: nej.md/4aia1Bv

#MedSky #Oncology
KRAS Oncoprotein Signaling in Cancer | NEJM
Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients.
nej.md
January 21, 2025 at 5:25 PM
A new post in Science Careers for our open-rank faculty search at the Hunter College Dept of Biological Sciences: jobs.sciencecareers.org/job/668588/o...
December 20, 2024 at 4:20 AM
It's been a delight to be a Mentor to a Postbac Scholar in Damon Runyon SPARK this year. College seniors interested in paid full time cancer research next year - I encourage you to apply to SPARK. @damonrunyon.org damonrunyon.org/for-scientists/application-guidelines/research
Damon Runyon Scholars Program for Advancing Research and Knowledge | Damon Runyon
damonrunyon.org
December 13, 2024 at 3:11 PM
Do you love science and want research experience before your next step? NY-RaMP is a 1 year paid opportunity for recent college graduates to do research in my lab or another lab at Hunter College. Learn more at a free webinar on Wed Dec 11 at 3 PM EST nyramp.org/webinars
December 9, 2024 at 2:14 PM
Cancer researchers: Are you a postdoc ready to launch your own lab? Or an Assistant/Associate/Full Professor seeking a change of scene? The Biological Sciences dept at Hunter College in New York City is hiring! Apply to our new open rank faculty search: bit.ly/huntercollegebiology
Jobs | City University of New York
bit.ly
December 4, 2024 at 6:03 PM
What an amazing team!
November 24, 2024 at 6:38 PM